Extended gastric residence of drugs can enhance the therapeutic effect, increase bioavailability, improve efficacy, and reduce the number of required doses by prolonging the retention of the drug delivery system. A new floating drug delivery for Ondansetron was designed and evaluated. Pre-formulation studies included the assessment of powder flow properties and drug-excipient compatibility. In-vitro release studies and a buoyancy test were performed to characterize the performance of the system. The study evaluated the properties of Ondansetron tablets. The optimized batches had compressibility index values ranging from 7.272 % to 25 %, with percentage weight fluctuation ranging from 0 to 1.05 %. The tablets were 2.92 and 3.52 mm thick, hardness between 3.50 and 4.65 kg/cm